Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Date:3/11/2009

http://www.3sbio.com

Safe Harbor Statement

Certain statements in this release that are not purely historical in nature, including the 2009 full year guidance information, statements contained in "2009 Full Year Guidance & Selected Company Objectives" section, and management comments, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon 3SBio management's current expectations, and actual results could differ materially. Among the factors that could cause 3SBio's actual results to differ from what the company currently anticipates may include: competition from other domestic and foreign pharmaceutical companies; the market conditions or pharmaceutical products in China; market acceptance of 3SBio products; hospital or patient demand for our products; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; its ability to develop and commercialize additional products or additional indications for existing products; its ability to analyze additional in-licensing opportunities; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. For additional information on these and other factors as well as risks, uncertainties and assumptions that may adversely and materially affect the 3SBio's business, financial conditions and results of operations, please refer to the company's filings with the Securities and Exchange Commission at
'/>"/>

SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...CAMBRIDGE, Mass., Dec. 2 TechConne...n technology development and product integration i... the December 11th deadline for technology abstrac...th year, TechConnect World, in association with th...d the Clean Technology and Sustainable Industries ...
(Date:12/2/2009)... NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simce...") (NYSE: SCR ), a leading pharmaceutical compan...and marketing of branded,generic and proprietary p...of,its drugs have been included in China,s Nationa...ed by China,s Ministry of Human Resources and Soci...
(Date:12/2/2009)...EN, N.J., Dec. 2 According to the ...cent of Americans diagnosed with diabetes already ... retinopathy, damage to the retina caused by leaky...eople with diabetes and is one of the most feared ... of all patients who,ve had diabetes for 10 years ...
(Date:12/1/2009)...NEW YORK, Dec. 1 Reportlinker.com ...ilable in its catalogue: ,, Industrial Enzymes...tlinker.com/p0164431/Industrial-Enzymes---A-Global...et is an oligopoly with few strong players and a h...ivities. Keen competition and commoditization char...
Breaking Biology Technology:Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10
...8 Kosan Biosciences,Incorporated (Nasdaq: KOSN )...and nine months ended September 30, 2007. Net los...30, 2007 were,$11.1 million and $19.2 million, or ...net loss of $7.5 million and $24.9 million, or $0....ear. Revenues were $1.9 million and $17.1 million...
... Inverness Medical,Innovations, Inc. (Amex: IMA ...ject to market and other conditions, 7,000,000 sha...helf registration statement in an,underwritten pub...Company,are also offering to sell up to 165,698 sh...expects to grant the underwriters a 30-day option ...
... Inverness Medical,Innovations (Amex: IMA ) toda...with Chemogen, Inc. for the worldwide manufacture ...of Mycobacterium, the primary,causative agent of t...prietary antibodies for the detection of Lipoarabi...iagnosis of current mycobacterial infection,(inclu...
Other Biology Technology:Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 2Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 3Inverness - Chemogen Establish Exclusive License for TB Antibodies 2
(Date:12/3/2009)... , The UK leads the world when it comes to invest...t Engineering and Physical Sciences Research Counc...t more is needed: "Scientific and engineering rese...nd and solar power solutions, but more investment ... solutions if we are to meet our carbon emission t...
(Date:12/2/2009)... , , PHILADELPHIA Children exposed to secondhand...ing lung cancer in adulthood, even if they never s... Cancer Epidemiology, Biomarkers & Prevention , a...search, as part of a special tobacco focus in the ...9,000 Americans will be diagnosed with lung cancer...
(Date:12/2/2009)... , , PHILADELPHIA Cigarette smoking and alcohol ...strongly predicts the patient,s future risk of dea...f a new study show a similar effect among those wh..., "Most cancer survivors are counseled to quit sm...y, 21 percent continued to smoke even after their ...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Fox Soccer Channel and Fox Sports en Espanol Renew Every Goal Saves A Life Campaign With Malaria No More 55723 1Fox Soccer Channel and Fox Sports en Espanol Renew Every Goal Saves A Life Campaign With Malaria No More 55723 2Fox Soccer Channel and Fox Sports en Espanol Renew Every Goal Saves A Life Campaign With Malaria No More 55723 3Fox Soccer Channel and Fox Sports en Espanol Renew Every Goal Saves A Life Campaign With Malaria No More 55723 4New Technology Helps Athletes Prevent Dehydration and Heat Related Illness 55720 1New Technology Helps Athletes Prevent Dehydration and Heat Related Illness 55720 2Secca 28R 29 Therapy An Effective and Minimally Invasive Option for Treating Bowel Incontinence Launched in the US 55717 1Secca 28R 29 Therapy An Effective and Minimally Invasive Option for Treating Bowel Incontinence Launched in the US 55717 2
...ide to make proteins, key building blocks of all o... the instructions for assembling them. , An Iowa...hanism involved in marking where these instruction...dition of The Journal of Biological Chemistry , M...emistry, biophysics and molecular biology, along w...
...-- Researchers at Weill Cornell Medical College in... date palm genome, unlocking many of its genetic s... and initial assembly of the date palm using the m...r of the Genomics Laboratory at Weill Cornell Medi...e date palm is extremely valuable to researchers w...
...t evolution and creationism are often shaped by wh...es, according to a University of Minnesota study p...rnal of the American Institute of Biological Scien...professors in the College of Biological Sciences, ...y classes at the University of Minnesota to learn ...
Other Biology News:Genetic secrets of date palm unlocked by researchers at Weill Cornell Medical College in Qatar 2U of Minnesota study finds high school teachers influence student views of evolution & creationism 2
Yeast-GFP Collection from Invitrogen
...s can be used for the identification of potential ...r renal and other diseases. Due to the fact that u...nts, it provides an attractive alternative to bloo...rs. The ProteoSpin Urine Protein Concentration Mi...
... has joined forces with the Mickle Laboratory Engi...Tissue Chopper. This tissue sectioning system has ...tabolic experiments and to be especially applicabl...opsy or from small organs. Its special features ca...
Yeast-GFP 96-well Plates from Invitrogen
Biology Products: